Loading...
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
BACKGROUND/AIMS: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the p...
Na minha lista:
| Udgivet i: | Turk J Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Turkish Society of Gastroenterology
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699569/ https://ncbi.nlm.nih.gov/pubmed/31418413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.18833 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|